Fount Bio’s Flī-Derm™ dermatology product demonstrates impressive aesthetic improvement in clinical study

The company will present results of its blinded study at the Dermatology Summit at JPM 2024 in San Francisco on January 7, 2024

CAMBRIDGE, MA December 11, 2023 – Life sciences innovator Fount Bio, Inc., today announced it has successfully completed its first clinical study demonstrating the safety and efficacy of its novel product for aesthetic dermatology. The product, Flī-Derm™, is based on the company’s proprietary Flī-HA bioorthogonal chemistry platform that enables the building of durable forms of hyaluronic acid (HA) on or within tissues via microneedling. Results of the study will be presented at the Dermatology Summit at the JPM Healthcare Conference in San Francisco on January 7, 2024.

The study, designed with blinded physician assessments, clearly demonstrates aesthetic improvement, including reducing fine lines and wrinkles, relative to control treatment. It also demonstrated exceptional safety and tolerability.

“These study results confirm the ability of our bioorthogonal chemistry platform to overcome key challenges associated with the delivery of hyaluronic acid,” said Fount Bio co-founder and CEO Doug Levinson, Ph.D. “As the lead product using our proprietary technology, Flī-Derm offers exciting possibilities for improving the health and well-being of patients. We look forward to presenting our study results with the clinical dermatology community at JPM 2024.”

Dr. Jeff Dover, M.D., one of Fount Bio’s clinical advisors, commented, “These encouraging clinical results support Flī-Derm’s potential to become an exciting new treatment option for patients and consumers seeking long-lasting improvement in skin quality. The high-tolerability profile and simplified, injectionless procedure should be very appealing to both patients and their providers.”

Fount Bio’s Flī-HA technology platform represents a novel approach to overcome key challenges associated with delivery of large glycopolymers like HA, allowing tailored placement onto tissue surfaces or within tissues where they are retained for extended periods of time. In addition to Fli-Derm, Fount Bio has pipeline efforts in ophthalmology and gynecology.

About Fount Bio

Fount Bio is a life science company developing a pipeline of innovative products for medical and beauty applications based on proprietary technology that combines innovations in biorthogonal chemistry and glycopolymer science. Led by an experienced management team and highly respected scientific advisors, Fount Bio combines scientific excellence, a pioneering spirit, and extensive experience in building high-value life sciences companies. The company is headquartered in Cambridge, Massachusetts, USA. Learn more at

Please direct press inquiries to or +1 ‪(617) 249-3552‬‬‬‬‬‬‬‬‬‬‬.